Novel ER Gene Fusion Identified in Luminal B Breast Cancer

Published in Nature Communications, the study identified a new gene fusion and rearrangement of the estrogen receptor, responsible for the aggressive nature of luminal B breast cancer.

Researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine have uncovered new information about the genetic alterations that may contribute to the development of a subtype breast cancer typically associated with more aggressive forms of the disease and higher recurrence rates.

The study, led by Dr. Xiaosong Wang, assistant professor of medicine — hematology and oncology and of molecular and cellular biology at Baylor, published today in Nature Communications and focused on the more aggressive molecular subtype of the estrogen-receptor positive breast cancer known as luminal B breast cancer.

“While expressing the estrogen receptor, the luminal B breast cancers usually have higher tumor grade, larger tumor size, and poor prognosis, with most cases difficult to treat by endocrine therapy,” said Wang, the lead and corresponding author on the report. “We wanted to gain a deeper understanding about the genetic alterations underlying this particular form of breast cancer, because we do not know about what malfunctions potentially cause this form to be more aggressive.”

Read the press release here: http://bit.ly/1oIjw0P

Source: Baylor College of Medicine